NASDAQ:CRNX Crinetics Pharmaceuticals Q2 2026 Earnings Report ProfileEarnings HistoryForecast Crinetics Pharmaceuticals EPS ResultsActual EPS-$1.14Consensus EPS -$1.18Beat/MissBeat by +$0.04One Year Ago EPS-$1.23Crinetics Pharmaceuticals Revenue ResultsActual Revenue$25.12 millionExpected Revenue$14.84 millionBeat/MissBeat by +$10.28 millionYoY Revenue Growth+2,336.90%Crinetics Pharmaceuticals Announcement DetailsQuarterQ2 2026Date8/3/2026TimeAfter Market ClosesConference Call DateMonday, August 3, 2026Conference Call Time4:00PM ETUpcoming EarningsCrinetics Pharmaceuticals' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Crinetics Pharmaceuticals Earnings HeadlinesHead-To-Head Review: Sonoma Pharmaceuticals (NASDAQ:SNOA) and Crinetics Pharmaceuticals (NASDAQ:CRNX)September 28, 2026 | americanbankingnews.comCrinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from S&P TMI IndexSeptember 3, 2026 | marketscreener.comMMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 8 at 1:00 AM | The Oxford Club (Ad)Crinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from S&P Global BMI IndexSeptember 3, 2026 | marketscreener.comMCrinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from S&P Pharmaceuticals Select Industry IndexSeptember 3, 2026 | marketscreener.comMVertex Pharmaceuticals Closes Crinetics Pharmaceuticals AcquisitionSeptember 1, 2026 | finance.yahoo.comSee More Crinetics Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Crinetics Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Crinetics Pharmaceuticals and other key companies, straight to your email. Email Address About Crinetics PharmaceuticalsCrinetics Pharmaceuticals (NASDAQ:CRNX) is a clinical-stage biopharmaceutical company focused on developing orally delivered, small-molecule therapies for endocrine conditions and other hormone-related diseases. The company’s research is centered on medicines designed to act on peptide hormone receptors, with the goal of providing alternatives to injectable therapies. Crinetics’ lead product candidate is paltusotine, an oral, selective somatostatin receptor type 2 agonist being developed for the treatment of acromegaly, a rare disorder caused by excessive growth hormone production. The company is also developing atumelnant, formerly known as CRN04894, an oral adrenocorticotropic hormone receptor antagonist being investigated for conditions including congenital adrenal hyperplasia and Cushing’s disease. Founded in 2008 and headquartered in San Diego, California, Crinetics conducts research and clinical development activities intended to serve patients in the United States and international markets. The company’s leadership includes founder and Chief Executive Officer Scott Struthers, Ph.D., who has guided the organization’s focus on orally administered therapies for endocrine disorders.View Crinetics Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Skydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand ExplodesWall Street Is Betting These 3 Beaten-Down Stocks Have More Room to RunLamb Weston’s Turnaround Is Starting to Look Real Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
